CN101677989A - 一种防治缺血性脑卒中的药物组合物及其制备方法 - Google Patents
一种防治缺血性脑卒中的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN101677989A CN101677989A CN200880001478A CN200880001478A CN101677989A CN 101677989 A CN101677989 A CN 101677989A CN 200880001478 A CN200880001478 A CN 200880001478A CN 200880001478 A CN200880001478 A CN 200880001478A CN 101677989 A CN101677989 A CN 101677989A
- Authority
- CN
- China
- Prior art keywords
- ligustilide
- separation
- separation reactor
- sedanolide
- extraction kettle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 35
- 229940079593 drug Drugs 0.000 title abstract description 22
- 230000002265 prevention Effects 0.000 title abstract description 6
- 208000032382 Ischaemic stroke Diseases 0.000 title abstract description 3
- UPJFTVFLSIQQAV-UHFFFAOYSA-N Sedanolide Chemical compound C1CCC2C(CCCC)OC(=O)C2=C1 UPJFTVFLSIQQAV-UHFFFAOYSA-N 0.000 claims abstract description 100
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 claims abstract description 58
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 claims abstract description 58
- PUQSUZTXKPLAPR-UJPOAAIJSA-N Gastrodin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(CO)C=C1 PUQSUZTXKPLAPR-UJPOAAIJSA-N 0.000 claims abstract description 24
- PUQSUZTXKPLAPR-KSSYENDESA-N 4-(beta-D-Glucopyranosyloxy) benzyl alcohol Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-KSSYENDESA-N 0.000 claims abstract description 23
- 229930193974 gastrodin Natural products 0.000 claims abstract description 23
- PUQSUZTXKPLAPR-NZEXEKPDSA-N helicidol Natural products O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](CO)O1)c1ccc(CO)cc1 PUQSUZTXKPLAPR-NZEXEKPDSA-N 0.000 claims abstract description 23
- 239000002904 solvent Substances 0.000 claims abstract description 16
- 239000007924 injection Substances 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 7
- 238000000926 separation method Methods 0.000 claims description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 239000000047 product Substances 0.000 claims description 45
- 238000000605 extraction Methods 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000000284 extract Substances 0.000 claims description 20
- 241000112528 Ligusticum striatum Species 0.000 claims description 19
- 239000003480 eluent Substances 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 239000012071 phase Substances 0.000 claims description 16
- 206010008092 Cerebral artery thrombosis Diseases 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 15
- 238000002390 rotary evaporation Methods 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 13
- 239000003208 petroleum Substances 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 229960001866 silicon dioxide Drugs 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000010829 isocratic elution Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 235000019198 oils Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 239000000312 peanut oil Substances 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 235000005687 corn oil Nutrition 0.000 claims description 2
- 239000002285 corn oil Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 description 11
- 239000004677 Nylon Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 206010008118 cerebral infarction Diseases 0.000 description 10
- 230000000857 drug effect Effects 0.000 description 10
- 229920001778 nylon Polymers 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000000302 ischemic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000002490 cerebral effect Effects 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 7
- 235000013350 formula milk Nutrition 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical group CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- KWWLGXNRLABSMP-UHFFFAOYSA-N phosphoric acid;2,3,5,6-tetramethylpyrazine Chemical compound OP(O)(O)=O.CC1=NC(C)=C(C)N=C1C KWWLGXNRLABSMP-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 231100000111 LD50 Toxicity 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 3
- 241000305491 Gastrodia elata Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 238000000205 computational method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 239000009064 mailuoning Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- MJPMPMZXJIZPRE-UHFFFAOYSA-N 3-butyl-5,6,7,7a-tetrahydro-3h-2-benzofuran-1-one Chemical compound C1CCC=C2C(CCCC)OC(=O)C21 MJPMPMZXJIZPRE-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 101800004637 Communis Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000244365 Ligusticum sinense Species 0.000 description 2
- 240000004980 Rheum officinale Species 0.000 description 2
- 235000008081 Rheum officinale Nutrition 0.000 description 2
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- HGUDVDQXCUHOED-YMQHIKHWSA-N [(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)O[C@@H]1[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1OC1=CC=C(CO)C=C1 HGUDVDQXCUHOED-YMQHIKHWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- FUESFIVIIFEDFI-UHFFFAOYSA-N octadecylsilicon Chemical compound CCCCCCCCCCCCCCCCCC[Si] FUESFIVIIFEDFI-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000013094 purity test Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZFJRGUPGFRAVKA-UHFFFAOYSA-N 1-butylcyclohexa-1,3-diene Chemical compound CCCCC1=CC=CCC1 ZFJRGUPGFRAVKA-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- ZPIKVDODKLJKIN-UHFFFAOYSA-N 3-butyl-4,5-dihydro-3h-2-benzofuran-1-one Chemical compound C1CC=CC2=C1C(CCCC)OC2=O ZPIKVDODKLJKIN-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 241000212948 Cnidium Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000700145 Petromus typicus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000144290 Sigmodon hispidus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 210000004491 foramen ovale Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930184727 ginkgolide Natural products 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229930183325 senkyunolide Natural products 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种防治缺血性脑卒中的药物组合物,该药物组合物由瑟丹酸内酯19~72%、蒿本内酯17~67%、天麻素2~29%和溶剂组成。本发明药物组合物药效高,可有效减轻缺血性脑卒中的病理变化和行为障碍;其次药效确切,用量小,作用强;此外本发明纯度高,纯度可达98%以上,可以制成包括注射剂在内的制剂。
Description
PCT国内申请,说明书已公开。
Claims (1)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2008/000349 WO2009100587A1 (zh) | 2008-02-14 | 2008-02-14 | 一种防治缺血性脑卒中的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101677989A true CN101677989A (zh) | 2010-03-24 |
CN101677989B CN101677989B (zh) | 2012-10-10 |
Family
ID=40956622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008800014789A Expired - Fee Related CN101677989B (zh) | 2008-02-14 | 2008-02-14 | 一种防治缺血性脑卒中的药物组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101677989B (zh) |
WO (1) | WO2009100587A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688253A (zh) * | 2012-05-15 | 2012-09-26 | 清华大学 | 改善脑缺血用的含有麻黄碱的注射液的制备方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102626390B (zh) * | 2012-04-19 | 2013-05-29 | 海南灵康制药有限公司 | 一种天麻素多相脂质体注射液 |
CN102698089B (zh) * | 2012-05-15 | 2014-03-05 | 清华大学 | 防治脑缺血用的含有麻黄碱提取物的口服液的制备方法 |
CN102688184B (zh) * | 2012-05-15 | 2013-10-16 | 清华大学 | 改善大鼠血液流变障碍用的含有麻黄碱注射液的制备方法 |
CN104415044B (zh) * | 2013-08-30 | 2018-10-16 | 陈震 | 一种治疗中风及其后遗症的药物组合物及其制剂 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60330679D1 (de) * | 2002-08-20 | 2010-02-04 | Univ Singapore | Phytoprogestogenen extrakten aus rhizoma ligusticum chuanxiong und ihre verwendungszwecke |
CN100404020C (zh) * | 2003-06-11 | 2008-07-23 | 长春大政药业科技有限公司 | 一种川芎挥发油软胶囊及其制备方法 |
CN1569848A (zh) * | 2003-07-14 | 2005-01-26 | 中国中医研究院中药研究所 | 治疗缺血性心脏病的川芎内酯及其制备方法 |
CN1559417A (zh) * | 2004-03-05 | 2005-01-05 | 嵩 张 | 天麻素静脉注射液及其制备方法 |
WO2007038610A2 (en) * | 2005-09-26 | 2007-04-05 | President & Fellows Of Harvard College | Use of natural products for treatment of neurological disorders |
CN1977839A (zh) * | 2005-12-05 | 2007-06-13 | 江西青峰药业有限公司 | 一种治疗脑血管疾病的药物组合物及其制备方法 |
CN1857622A (zh) * | 2006-03-30 | 2006-11-08 | 欧苏 | 包含天麻和川芎有效成分的药物组合物及制剂 |
CN100589831C (zh) * | 2006-05-31 | 2010-02-17 | 本溪市中心医院 | 大川芎干粉制剂的制备方法 |
CN101015552A (zh) * | 2006-12-29 | 2007-08-15 | 天津大学 | 一种川芎内酯提取物及其制备方法和应用 |
-
2008
- 2008-02-14 WO PCT/CN2008/000349 patent/WO2009100587A1/zh active Application Filing
- 2008-02-14 CN CN2008800014789A patent/CN101677989B/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688253A (zh) * | 2012-05-15 | 2012-09-26 | 清华大学 | 改善脑缺血用的含有麻黄碱的注射液的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101677989B (zh) | 2012-10-10 |
WO2009100587A1 (zh) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4943846B2 (ja) | 循環器疾患および脳血管疾患の処置のための薬学的組成物 | |
CN105999159B (zh) | 一种黑糖雪莲组合物及其制备方法 | |
CN101677989A (zh) | 一种防治缺血性脑卒中的药物组合物及其制备方法 | |
CN1814170B (zh) | 一种治疗心血管疾病的药物滴丸及其制备方法 | |
CN112057501A (zh) | 用于治疗肌肉萎缩与肌无力的中药组合物、中药药膏及外用热敷膏药贴 | |
CN105148220A (zh) | 一种治疗脾肾阳虚型眩晕的中药及制备方法 | |
CN101176751B (zh) | 丹参和桂枝的药物组合物 | |
CN111991519A (zh) | 一种治疗慢阻肺的藏药组合物及其制备方法 | |
CN111419946A (zh) | 一种治疗不育症的药物及其制备方法 | |
CN105748553A (zh) | 一种活血消肿解毒的中药组合物及其制备方法 | |
CN105853766A (zh) | 一种中药制剂在制备治疗原发性高血压药物中的用途 | |
CN105288173A (zh) | 一种调经祛斑的中药微丸制剂及制备方法 | |
CN103169856B (zh) | 一种含有黄连的中药组合物 | |
CN108743654B (zh) | 一种用于治疗缺血性心脏病的中药组合物及其制备方法和应用 | |
CN112294915B (zh) | 一种治疗肺气肿的药物组合物及其制备方法 | |
CN101152247A (zh) | 用于心脑血管疾病的药物组合物及其制备方法 | |
CN107320528A (zh) | 一种治疗再生障碍性贫血的中药提取物及药物 | |
CN101244127B (zh) | 用于治疗血管性痴呆症的药物 | |
CN104491454A (zh) | 一种治疗肝阳上亢型眩晕的中药及制备方法 | |
CN105031286A (zh) | 一种治疗缺铁性贫血的中药制剂及其制备方法 | |
CN103239611A (zh) | 一种含有甘草的中药组合物 | |
CN104887964A (zh) | 一种治疗积痰阻脉型眩晕的中药及制备方法 | |
CN105012731A (zh) | 一种预防产后出血的中药及其制备方法 | |
CN103239609A (zh) | 一种含有麦冬的中药组合物 | |
CN103182021A (zh) | 一种含有地黄的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 Termination date: 20160214 |
|
CF01 | Termination of patent right due to non-payment of annual fee |